Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.
June 2017
Thu, 29/06/2017 - 07:30
Mon, 26/06/2017 - 07:30
Coventry, UK, 26th June 2017 / Sciad Newswire / Medherant Ltd, a University of Warwick spin-out company developing a nex
Thu, 22/06/2017 - 07:00
First acquisition made by Invent Farma / neuraxpharm following the creation of the Group by funds advised by Apax Partners in August 2016
Wed, 14/06/2017 - 07:30
Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks.
Mon, 12/06/2017 - 07:30
Coventry, UK, 12th June 2017 / Sciad Newswire / Medherant Ltd, a University of Warwick spin-out company developing a nov
Tue, 06/06/2017 - 07:30
Coventry, UK, 6th June 2017 / Sciad Newswire / Medherant Ltd, a University of Warwick spin-out company developing a nove